Endocrinología Diabetes y Nutrición, Год журнала: 2024, Номер unknown
Опубликована: Дек. 1, 2024
Archives of Gynecology and Obstetrics, Год журнала: 2025, Номер 311(5), С. 1241 - 1247
Опубликована: Янв. 7, 2025
Abstract Purpose Metabolic disease, including obesity and type 2 diabetes, are amongst the most significant health issues facing women of reproductive age. To date, no antenatal weight management tools have reduced risk adverse outcomes for with their offspring, resulting in a shift focus to pre-conception period. Although not yet recognised international guidelines, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) being increasingly used prior conception. Methods A literature search PubMed, Medline, Embase databases identified relevant articles describing use GLP-1 RAs during pregnancy. Papers were selected based on relevance originality, clinical trials, large observational studies meta-analyses preferentially included. Results This narrative review summarises mechanism action effects observed non-pregnant adults. It synthesises available data from human animal regarding safety efficacy pregnancy, consequences inadvertent drug exposure early In considering need balance risks metabolic disease posed by exposure, it highlights areas where further research is needed guide decision-making. Conclusion may role facilitating loss improving However, there currently insufficient evidence demonstrate that this class drugs pregnancy improves outcomes.
Язык: Английский
Процитировано
1
Obstetrics and Gynecology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 23, 2025
Obesity is a chronic condition that causes significant morbidity and mortality in people the United States around world. Traditional means of weight loss include diet, exercise, behavioral modifications, surgery. New medications, glucagon-like peptide-1 receptor agonists, are revolutionizing management but have implications for fertility pregnancy. associated with infertility may affect response to ovulation induction medications. In pregnancy, obesity increases risks spontaneous abortion, birth defects, gestational diabetes, hypertensive disorders cesarean delivery, stillbirth. Lifestyle changes alone not improved outcomes. Glucagon-like agonists new medications targeting gut hormones can help achieve their goals contraindicated Obstetrician-gynecologists should work patients manage these before they become pregnant, between pregnancies, after delivery.
Язык: Английский
Процитировано
1
Biomolecules, Год журнала: 2025, Номер 15(3), С. 408 - 408
Опубликована: Март 13, 2025
Worldwide, nearly 40% of adults are overweight and 13% obese. Health consequences excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, increased mortality. Treating obesity is challenging calorie restriction often leads to rebound gain. Treatments such as bariatric surgery create hesitancy among patients due their invasiveness. GLP-1 medications have revolutionized loss can reduce body in obese by between 15% 25% on average after about 1 year. Their mode action mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism satiety. However, drugs carry known risks and, since use for recent, may unforeseen well. They a boxed warning people with personal or family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) fairly common while pancreatitis obstruction rarer. There be lean mass well premature facial aging. A significant disadvantage using these high rate regain when they discontinued. Achieving success pharmacologic treatment then weaning avoid future negative effects would ideal.
Язык: Английский
Процитировано
1
International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(3), С. 1295 - 1295
Опубликована: Фев. 3, 2025
Recurrent pregnancy loss (RPL) is defined as the occurrence of two or more consecutive losses before 24 weeks gestation. It affects 3-5% women who are attempting to conceive. RPL can stem from a variety causes and frequently associated with psychological distress diminished quality life. By contrast, recurrent implantation failure (RIF) refers inability achieve successful after three high-quality embryo transfers at least instances egg donation. RIF shares several causative factors RPL. The immunological underpinnings these conditions involve alterations in uterine NK cells, reductions M2 macrophages myeloid-derived suppressor an increased Th1/Th2 ratio, decreased Treg/Th17 presence shared ≥3 HLA alleles between partners, autoimmune disorders. Various therapeutic approaches have been employed address concerns, achieving varying degrees success, although some therapies remain contentious within medical community. This review intends explore implicated analyze treatments for conditions, which may include steroids, intravenous immunoglobulins, calcineurin inhibitors, anti-TNF antibodies, intralipid infusions, granulocyte colony-stimulating factor, lymphocyte immunotherapy.
Язык: Английский
Процитировано
0
Endocrinología Diabetes y Nutrición (English ed ), Год журнала: 2025, Номер unknown, С. 101531 - 101531
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Advances in Clinical Medicine, Год журнала: 2025, Номер 15(03), С. 1646 - 1653
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Current Opinion in Obstetrics & Gynecology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 4, 2025
Purpose of review This summarizes research on glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and their relevance in the treatment benign gynecologic conditions. Recent findings GLP-1 RA use is increasing popularity USA, with expanding applications for gynecology. may improve weight loss, metabolic dysfunction, menstrual regularity patients polycystic ovarian syndrome (PCOS). Side effects these medications, including delayed gastric emptying, impact perioperative management, efficacy oral contraception tirzepatide. Research ongoing infertility endometrial hyperplasia treatment. studies showed a higher spontaneous conception rate pregnancy combined metformin therapy when taken before IVF. Further are needed to establish recommendations medication treating Summary With obesity, diabetes, cardiovascular disease rise also increasing. RAs currently indicated diabetes glycemic control, addition loss management. Gynecologists must consider implications disorders, such as PCOS, contraceptive care, potential impacts hyperplasia.
Язык: Английский
Процитировано
0
Seminars in Perinatology, Год журнала: 2025, Номер unknown, С. 152081 - 152081
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
Gefässchirurgie, Год журнала: 2025, Номер unknown
Опубликована: Апрель 28, 2025
Процитировано
0
Diabetes Obesity and Metabolism, Год журнала: 2025, Номер unknown
Опубликована: Май 6, 2025
Abstract Aims The prevalence of diabetes and obesity continues to rise in women reproductive age, with significant implications for both mother foetus. Glucagon‐like peptide‐1 receptor agonists are effective treatments obesity. However, no currently approved use during pregnancy. We describe the outcomes unplanned pregnancies regulatory clinical trials submitted Food Drug Administration European Medicines Agency. Materials Methods A search was conducted documentation published by Agency on agonists. Clinical Medical Reviews Center Evaluation Research at every agonist prior market authorisation were assessed gather information that occurred while females partaking development programmes such drugs. Results Evidence having planned is lacking, only evidence thus far relies occurring inadvertently trials. incidence congenital abnormalities humans appears relatively low following Conclusions Key knowledge gaps must be addressed before introduction class drugs pregnant women. Currently, should stopped as soon patient becomes aware a establishment registries designed capture data relating cases exposure pregnancy high priority, where already exist, findings need published.
Язык: Английский
Процитировано
0